880596-70-3

Upstream product

• 63349-52-0 methyl 4-iodophenylacetate 
• 932725-73-0 methyl 4-[diethyl phosphono(difluoromethyl)]phenylacetate 
• 880596-26-9 methyl 4-[O-(5-nitro)furfuryl N-methyl-N-(4-chlorobutyl) phosphono(difluoromethyl)]phenylacetate 
• 1798-06-7 (4-iodophenyl)acetic acid 
• 880595-47-1 methyl 4-[chloro-N-methyl-N-(4-chlorobutyl) phosphono(difluoromethyl)]phenylacetate 

Downstream Products

• 932725-87-6 4-[O-(5-nitro)furfuryl N-methyl-N-(4-chlorobutyl) phosphono(difluoromethyl)]phenylacetic-(L)-aspartic acid β-tert-butyl ester α-methyl ester 
• 932725-90-1 C₄₇H₅₉Cl₂F₄N₇O₁₅P₂ 
• 932725-89-8 4-[O-(5-nitro)furfuryl N-methyl-N-(4-chlorobutyl) phosphono(difluoromethyl)]phenylacetic-(L)-aspartic acid β-tert-butyl ester 

Relevant academic research and scientific papers

Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug

Our laboratory recently reported the development of novel prodrug chemistry for the intracellular delivery of phosphotyrosine mimetics. This chemistry has now been adapted for the synthesis of a prodrug that delivers the nonhydrolyzable difluoromethylphos

PRODRUGS OF DRUG-PHOSPHATE CONJUGATES AND ANALOGS THEREOF

Phosphate-substituted therapeutic compounds and analogs thereof that may serve as prodrugs are described. The prodrugs may include phosphorus-containing compounds, drug-phosphate conjugates, and analogs of drug-phosphate conjugates. Also described are ana